Who are Desmopressin Injectable Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): desmopressin MELT formulation, terlipressin (vasoconstrictor), DDAVP Inhalant Product, Terlipressin & then Dummy, desmopressin tablet, Terlipressin plus standard care.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/desmopressin-injectable-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Desmopressin Injectable Solution — Competitive Intelligence Brief

Desmopressin Injectable Solution (Desmopressin Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin analog. Area: Endocrinology.

phase 3 Vasopressin analog V2 receptor (vasopressin receptor 2) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Desmopressin Injectable Solution (Desmopressin Injectable Solution) — Hamilton Health Sciences Corporation. Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Desmopressin Injectable Solution TARGET	Desmopressin Injectable Solution	Hamilton Health Sciences Corporation	phase 3	Vasopressin analog	V2 receptor (vasopressin receptor 2)
desmopressin MELT formulation	desmopressin MELT formulation	University Hospital, Ghent	marketed	Vasopressin analog / Antidiuretic agent	V2 vasopressin receptor
terlipressin (vasoconstrictor)	terlipressin (vasoconstrictor)	National Science and Technology Council, Taiwan	marketed	Vasopressin analog	Vasopressin V1 receptor
DDAVP Inhalant Product	DDAVP Inhalant Product	Nationwide Children's Hospital	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor; V1 vasopressin receptor
Terlipressin & then Dummy	Terlipressin & then Dummy	Aga Khan University	marketed	Vasopressin analog	Vasopressin V1 receptor
desmopressin tablet	desmopressin tablet	University Hospital, Ghent	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor
Terlipressin plus standard care	Terlipressin plus standard care	Shanghai Zhongshan Hospital	phase 3	Vasopressin analogue	Vasopressin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin analog class)

Aga Khan University · 1 drug in this class
Hamilton Health Sciences Corporation · 1 drug in this class
National Science and Technology Council, Taiwan · 1 drug in this class
University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desmopressin Injectable Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/desmopressin-injectable-solution. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab